Treatment of Alzheimer's disease with acetylcholinesterase inhibitors

Bridging the gap between evidence and practice

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Views on drug therapy with acetylcholinesterase inhibitors of the cognitive symptoms of Alzheimer's disease are not uniform, varying from excitement at the possibility of significantly improving the personal and social burden of the disease to skeptical and nihilistic attitudes. Clinical practice from generous prescription to evidence-based guidelines and advising much stricter rules, mirror these attitudes. The epidemiological and clinical relevance of the issue requires understanding of the factors responsible for such discrepancies. Randomized clinical trials have only been able to address a few of the many variables that can affect the response to acetylcholinesterase inhibitors. The effect on behavioral symptoms, severe Alzheimer's dementia, and non-Alzheimer's forms of degenerative dementia need to be clarified as well as the modulating effect of frequently associated conditions such as cognitive changes due to physical diseases and cerebrovascular disease. The gap between evidence and clinical practice might be closed with appropriately designed observational studies rather than randomized clinical trials.

Original languageEnglish
Pages (from-to)551-557
Number of pages7
JournalJournal of Neurology
Volume248
Issue number7
DOIs
Publication statusPublished - 2001

Fingerprint

Cholinesterase Inhibitors
Alzheimer Disease
Randomized Controlled Trials
Cerebrovascular Disorders
Behavioral Symptoms
Neurobehavioral Manifestations
Observational Studies
Prescriptions
Dementia
Guidelines
Drug Therapy
Therapeutics

Keywords

  • Alzheimer's disease
  • Clinical trials
  • Donepezil
  • Galantamine
  • Rivastigmine
  • Therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

@article{ceeb391662c241abb750803942035e67,
title = "Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: Bridging the gap between evidence and practice",
abstract = "Views on drug therapy with acetylcholinesterase inhibitors of the cognitive symptoms of Alzheimer's disease are not uniform, varying from excitement at the possibility of significantly improving the personal and social burden of the disease to skeptical and nihilistic attitudes. Clinical practice from generous prescription to evidence-based guidelines and advising much stricter rules, mirror these attitudes. The epidemiological and clinical relevance of the issue requires understanding of the factors responsible for such discrepancies. Randomized clinical trials have only been able to address a few of the many variables that can affect the response to acetylcholinesterase inhibitors. The effect on behavioral symptoms, severe Alzheimer's dementia, and non-Alzheimer's forms of degenerative dementia need to be clarified as well as the modulating effect of frequently associated conditions such as cognitive changes due to physical diseases and cerebrovascular disease. The gap between evidence and clinical practice might be closed with appropriately designed observational studies rather than randomized clinical trials.",
keywords = "Alzheimer's disease, Clinical trials, Donepezil, Galantamine, Rivastigmine, Therapy",
author = "Frisoni, {Giovanni B.}",
year = "2001",
doi = "10.1007/s004150170131",
language = "English",
volume = "248",
pages = "551--557",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "7",

}

TY - JOUR

T1 - Treatment of Alzheimer's disease with acetylcholinesterase inhibitors

T2 - Bridging the gap between evidence and practice

AU - Frisoni, Giovanni B.

PY - 2001

Y1 - 2001

N2 - Views on drug therapy with acetylcholinesterase inhibitors of the cognitive symptoms of Alzheimer's disease are not uniform, varying from excitement at the possibility of significantly improving the personal and social burden of the disease to skeptical and nihilistic attitudes. Clinical practice from generous prescription to evidence-based guidelines and advising much stricter rules, mirror these attitudes. The epidemiological and clinical relevance of the issue requires understanding of the factors responsible for such discrepancies. Randomized clinical trials have only been able to address a few of the many variables that can affect the response to acetylcholinesterase inhibitors. The effect on behavioral symptoms, severe Alzheimer's dementia, and non-Alzheimer's forms of degenerative dementia need to be clarified as well as the modulating effect of frequently associated conditions such as cognitive changes due to physical diseases and cerebrovascular disease. The gap between evidence and clinical practice might be closed with appropriately designed observational studies rather than randomized clinical trials.

AB - Views on drug therapy with acetylcholinesterase inhibitors of the cognitive symptoms of Alzheimer's disease are not uniform, varying from excitement at the possibility of significantly improving the personal and social burden of the disease to skeptical and nihilistic attitudes. Clinical practice from generous prescription to evidence-based guidelines and advising much stricter rules, mirror these attitudes. The epidemiological and clinical relevance of the issue requires understanding of the factors responsible for such discrepancies. Randomized clinical trials have only been able to address a few of the many variables that can affect the response to acetylcholinesterase inhibitors. The effect on behavioral symptoms, severe Alzheimer's dementia, and non-Alzheimer's forms of degenerative dementia need to be clarified as well as the modulating effect of frequently associated conditions such as cognitive changes due to physical diseases and cerebrovascular disease. The gap between evidence and clinical practice might be closed with appropriately designed observational studies rather than randomized clinical trials.

KW - Alzheimer's disease

KW - Clinical trials

KW - Donepezil

KW - Galantamine

KW - Rivastigmine

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0034939380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034939380&partnerID=8YFLogxK

U2 - 10.1007/s004150170131

DO - 10.1007/s004150170131

M3 - Article

VL - 248

SP - 551

EP - 557

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 7

ER -